|
시장보고서
상품코드
2058221
골격이형성증 시장 : 질환 유형별, 치료법별, 투여 경로별, 최종사용자별, 지역별Skeletal Dysplasia Market, By Disorder Type, By Treatment Type, By Route of Administration, By End User, By Geography |
||||||
골격이형성증 시장은 2026년에 48억 달러로 추정되며, 2033년까지 97억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 10.6%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 48억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 10.60% | 2033년 시장 규모 예측: | 97억 달러 |
골격이형성증은 뼈와 연골의 발달에 영향을 미쳐 골격의 성장, 구조, 기능에 이상을 초래하는 400여 가지 이상의 희귀 유전성 질환으로 구성된 다양한 그룹입니다. 연골무형성증, 골형성부전증, 뮤코다당증, 저포스파타제증 등 유전적으로 다양한 이러한 질환에는 목표가 명확한 장기적인 임상 관리가 필요합니다. 질병에 대한 인식이 높아지고 유전학 및 분자진단 기술이 발전함에 따라, 전 세계적으로 더욱 조기적이고 효과적인 진단이 가능해지고 있습니다.
최근 몇 년간 치료 옵션의 확대와 연구 자금의 증가에 따라, 골격이형성증은 희귀질환 치료 분야에서 큰 주목을 받고 있습니다. 골격 형성 부전의 관리에는 효소 보충 요법, 성장호르몬 요법, 비스포스포네이트 제제, 골격 이상에 대한 외과적 교정 등 여러 가지 치료 전략이 사용되고 있습니다. 또한, 최근에는 더욱 적극적으로 연구되고 있는 유전자 치료의 일환으로, 질환 자체를 교정하는 경우도 있습니다. 의사들이 골격이형성증에 지속적으로 주목하고 있는 점, 희귀질환 치료제 지정과 같은 지원적 규제 조치, 의료 부문 전체의 지출 증가, 그리고 첨단 진단 도구의 이용 가능성 등이 이 시장의 혁신에 영향을 미치는 요인 중 일부입니다.
시장 역학
전 세계 골격이형성증 시장은 시장 성장 전망과 치료법의 발전은 물론, 주로 약리학적 기회의 개선에 힘입어 성장하고 있습니다. 그 밖의 성장 요인으로는 진단 기술의 발전에 따른 유전성 질환의 부담 증가, 환자 및 의료 종사자들의 건강 관리에 대한 인식 제고, 그리고 희귀질환 치료제를 위한 프로그램 투자 등을 들 수 있습니다. 희귀질환 치료제 지정이나 패스트트랙 승인 절차와 같은 유리한 규제 정책은 제약 기업에 시장 독점권을 부여하는 동시에 개발 기간을 대폭 단축시킵니다. 신흥 시장의 헬스케어 인프라 확충과 희귀 질환 치료를 뒷받침하는 정부의 노력에 힘입어 가처분 소득이 증가함에 따라, 시장 접근성과 고객 기반이 더욱 확대될 것입니다.
그러나 희귀질환 치료에 드는 높은 비용으로 인해 시장 성장이 크게 저해되고 있습니다. 복잡한 규제 승인 절차와 엄격한 안전성 요건은 의약품 개발 과정을 더욱 길어지게 하고 비용을 증가시키고 있습니다. 또한, 임상의들의 희귀 골질환에 대한 인식 부족에 더해, 표현형의 다양성이 진단상의 딜레마를 초래하여 진단 지연이나 부정확성을 야기하고 있어, 고객층 전체의 요구를 충족시키지 못하고 있습니다. 이러한 헬스케어 환경에는 더 높은 치료 가치를 보장하는 맞춤형 의료, 유전자 치료 기술, 그리고 새로운 약물전달 시스템에 대한 수요 등 큰 기회가 존재합니다. 연구 기관, 생명공학 기업, 제약사 간의 협력은 물론, 희귀질환에 대한 의료 보장 확대와 희귀질환 치료제(오르판 드럭) 개발 프로그램에 대한 투자 증가는 밸류체인에 참여하는 각 주체에게 풍부한 기회를 제공하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표를 바탕으로 전 세계 골격이형성증 시장의 주요 기업 개요을 작성하였습니다 : 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계 골격이형성증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 골격 이형성 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 골격이형성증 시장 : 질환 유형별, 2021-2033년
제5장 세계의 골격이형성증 시장 : 치료 유형별, 2021-2033년
제6장 세계의 골격이형성증 시장 : 투여 경로별, 2021-2033년
제7장 세계의 골격이형성증 시장 : 최종사용자별, 2021-2033년
제8장 세계의 골격이형성증 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고문헌 및 조사 방법
KSM 26.06.19Skeletal Dysplasia Market is estimated to be valued at USD 4.8 Bn in 2026 and is expected to reach USD 9.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.60% | 2033 Value Projection: | USD 9.7 Bn |
Skeletal dysplasias are a diverse group of more than 400 rare genetic diseases impacting on the development of bone and cartilage, resulting in abnormal skeletal growth, structure and function. These genetically heterogeneous conditions including achondroplasia, osteogenesis imperfecta, mucopolysaccharidoses, and hypophosphatasia require targeted and long-term clinical management. Growing disease awareness and advancements in genetics and molecular diagnostics are enabling earlier and more effective diagnosing across the world.
During the past few years, skeletal dysplasias has been gaining considerable traction in the rare disease therapeutics domain, owing to the expanding pool of treatment options and increased funding for its research. Several therapeutic strategies are being used in the management of skeletal dysplasias, for example, enzyme replacement therapies, growth hormone therapies, bisphosphonates, surgical correction of skeletal abnormalities and in some cases, as a part of the more aggressively pursued gene therapy these days, the correction of the search term itself. Sustained physician focus on skeletal dysplasias, supportive regulatory measures like orphan drug status permissions, growing overall health sector expenditure and accessibility of sophisticated diagnostic tools are some factors influencing this market's innovation.
Market Dynamics
The global skeletal dysplasia market is primarily driven by improving pharmacological opportunities in addition to market growth prospects and advancing therapy options. Other growth drivers such as the burden of genetic disorders due to diagnostic advancements, extensive awareness of healthcare to patients as well as to healthcare providers and investments in orphan drug programs for rare diseases. Favorable regulatory policies such as orphan drug designations and fast track approval procedures greatly reduce development time along with providing market exclusive rights to pharma companies. Growing healthcare infrastructure in emerging markets, rising disposable income supported by government initiatives favoring treatment in rare diseases further enhances market access and customer base.
However, market growth is hindered significantly due to high treatment costs for therapies of rare diseases. Complex regulatory approval processes and high safety demand further make drug development process extensive and costly. Also, clinicians' inability to recognize rare skeletal disease in addition to phenotypical variability leading to diagnostic dilemma results in late or inaccurate diagnosis hence not catering to the needs of entire customer population. Significant opportunities exist in this healthcare landscape such as the need for personalized medicine, gene therapy techniques, and novel drug delivery systems that assure a higher therapeutic value. Collaborations between research institutes, biotech and pharma companies along with increased healthcare coverage for rare diseases, rising investments in orphan drugs development programs opens up ample opportunities for players in the value chain.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global skeletal dysplasia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include BioMarin Pharmaceutical, Ascendis Pharma, BridgeBio Pharma, Pfizer, Novo Nordisk, Alexion Pharmaceuticals Takeda Pharmaceutical, Amgen, Ultragenyx Pharmaceutical, and Sanofi
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global skeletal dysplasia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skeletal dysplasia market
Market Segmentation
- Disorder Type Insights (Revenue, USD Bn, 2021 - 2033)
- Achondroplasia
- Osteogenesis Imperfecta
- Hypophosphatasia
- Thanatophoric Dysplasia
- Multiple Epiphyseal Dysplasia
- Others
- Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
- Drug Therapy
- Growth Hormone Therapy
- Surgical Interventions
- Physical Therapy and Rehabilitation
- Gene Therapy
- Others
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Injectable
- Oral
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Rehabilitation Centers
- Academic and Research Institutes
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- BioMarin Pharmaceutical
- Ascendis Pharma
- BridgeBio Pharma
- Pfizer
- Novo Nordisk
- Alexion Pharmaceuticals
- Takeda Pharmaceutical
- Amgen
- Ultragenyx Pharmaceutical
- Sanofi
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Skeletal Dysplasia Market, By Disorder Type
- Global Skeletal Dysplasia Market, By Treatment Type
- Global Skeletal Dysplasia Market, By Route of Administration
- Global Skeletal Dysplasia Market, By End User
- Global Skeletal Dysplasia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Skeletal Dysplasia Market, By Disorder Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Achondroplasia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Osteogenesis Imperfecta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hypophosphatasia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Thanatophoric Dysplasia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Multiple Epiphyseal Dysplasia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Skeletal Dysplasia Market, By Treatment Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Growth Hormone Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Surgical Interventions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Physical Therapy and Rehabilitation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Skeletal Dysplasia Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Skeletal Dysplasia Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Rehabilitation Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Skeletal Dysplasia Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disorder Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- BioMarin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ascendis Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BridgeBio Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alexion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ultragenyx Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
